sj-docx-2-taw-10.1177_20420986241227014 – Supplemental material for Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study

Supplemental material, sj-docx-2-taw-10.1177_20420986241227014 for Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study by Fahad Shaikh, Rochelle Wynne, Ronald L. Castelino, Sally C. Inglis, Patricia M. Davidson and Caleb Ferguson in Therapeutic Advances in Drug Safety</p

sj-docx-1-taw-10.1177_20420986241227014 – Supplemental material for Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study

Supplemental material, sj-docx-1-taw-10.1177_20420986241227014 for Direct oral anticoagulant use in hospitalized patients with atrial fibrillation across body mass index categories: design and rationale for a retrospective cohort study by Fahad Shaikh, Rochelle Wynne, Ronald L. Castelino, Sally C. Inglis, Patricia M. Davidson and Caleb Ferguson in Therapeutic Advances in Drug Safety</p

Data_Sheet_1_Chinese Version of the mHealth App Usability Questionnaire: Cross-Cultural Adaptation and Validation.doc

BackgroundMobile health (mHealth) apps have shown the advantages of improving medication compliance, saving time required for diagnosis and treatment, reducing medical expenses, etc. The World Health Organization (WHO) has recommended that mHealth apps should be evaluated prior to their implementation to ensure their accuracy in data analysis.ObjectiveThis study aimed to translate the patient version of the interactive mHealth app usability questionnaire (MAUQ) into Chinese, and to conduct cross-cultural adaptation and reliability and validity tests.MethodsThe Brislin’s translation model was used in this study. The cross-cultural adaptation was performed according to experts’ comments and the results of prediction test. The convenience sampling method was utilized to investigate 346 patients who used the “Good Doctor” (“Good Doctor” is the most popular mHealth app in China), and the reliability and validity of the questionnaire were evaluated as well.ResultsAfter translation and cross-cultural adaptation, there were a total of 21 items and 3 dimensions: usability and satisfaction (8 items), system information arrangement (6 items), and efficiency (7 items). The content validity index was determined to be 0.952, indicating that the 21 items used to evaluate the usability of the Chinese version of the MAUQ were well correlated. The Cronbach’s α coefficient of the total questionnaire was 0.912, which revealed that the questionnaire had a high internal consistency. The values of test-retest reliability and split-half reliability of the Chinese version of the MAUQ were 0.869 and 0.701, respectively, representing that the questionnaire had a good stability.ConclusionThe translated questionnaire has good reliability and validity in the context of Chinese culture, and it could be used as a usability testing tool for the patient version of interactive mHealth apps.</p

Participant demographics and clinical characteristics.

Participant demographics and clinical characteristics.</p

Types and costs of medications prescribed in the three months prior to screening.

Types and costs of medications prescribed in the three months prior to screening.</p

Table 1 medicare benefits schedule categories.

BackgroundAbout 70% of patients with advanced cancer experience pain. Few studies have investigated the use of healthcare in this population and the relationship between pain intensity and costs.MethodsAdults with advanced cancer and scored worst pain ≥ 2/10 on a numeric rating scale (NRS) were recruited from 6 Australian oncology/palliative care outpatient services to the Stop Cancer PAIN trial (08/15-06/19). Out-of-hospital, publicly funded services, prescriptions and costs were estimated for the three months before pain screening. Descriptive statistics summarize the clinico-demographic variables, health services and costs, treatments and pain scores. Relationships with costs were explored using Spearman correlations, Mann-Whitney U and Kruskal-Wallis tests, and a gamma log-link generalized linear model.ResultsOverall, 212 participants had median worst pain scores of five (inter-quartile range 4). The most frequently prescribed medications were opioids (60.1%) and peptic ulcer/gastro-oesophageal reflux disease (GORD) drugs (51.6%). The total average healthcare cost in the three months before the census date was A$6,742 (95$5,637, $7,847), approximately$27,000 annually. Men had higher mean healthcare costs than women, adjusting for age, cancer type and pain levels (men $7,872, women$4,493, pConclusionsIn this population with pain and cancer, there was no clear relationship between healthcare costs and pain severity. These treatment patterns requiring further exploration including the prevalence of peptic ulcer/GORD drugs, and lipid lowering agents and the higher healthcare costs for men.Trial registrationACTRN12615000064505. World Health Organisation unique trial number U1111–1164–4649. Registered 23 January 2015.</div

Supplemental Material - Feasibility of a Multi-Component Strengths-Building Intervention for Caregivers of Persons With Heart Failure

Supplemental Material for Feasibility of a Multi-Component Strengths-Building Intervention for Caregivers of Persons With Heart Failure by Martha Abshire Saylor, Noelle Pavlovic, Lyndsay DeGroot, Anna Peeler, Katie E. Nelson, Nancy Perrin, Nisha A. Gilotra, Jennifer L. Wolff, Patricia M. Davidson, and Sarah L. Szanton in Journal of Applied Gerontology</p

Table 6 association between clinico-demographics and mean total healthcare costs.

Table 6 association between clinico-demographics and mean total healthcare costs.</p

Table 7 association between clinico-demographics and mean total MBS and PBS costs.

Table 7 association between clinico-demographics and mean total MBS and PBS costs.</p

Medicare benefits schedule service use and costs in the three months prior to screening.

Medicare benefits schedule service use and costs in the three months prior to screening.</p